Compare PDSB & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDSB | NMTC |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 34.3M |
| IPO Year | 2015 | 2010 |
| Metric | PDSB | NMTC |
|---|---|---|
| Price | $0.66 | $0.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.00 | $1.98 |
| AVG Volume (30 Days) | ★ 370.9K | 242.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.90 | ★ 80.43 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,097,692.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $32.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 163.47 |
| 52 Week Low | $0.60 | $0.40 |
| 52 Week High | $1.90 | $1.15 |
| Indicator | PDSB | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 39.54 | 58.40 |
| Support Level | $0.60 | $0.70 |
| Resistance Level | $1.16 | $0.86 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 43.70 | 74.96 |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.